Back to Search
Start Over
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC
- Source :
- Journal of hepatology. 29(1)
- Publication Year :
- 1998
-
Abstract
- Background/Aims: Lipiodol chemoembolization is a widely used method of treatment in patients with unresectable hepatocellular carcinoma, but its efficacy is still debated. The aim of our study was to assess the efficacy of lipiodol chemoembolization in patients with unresectable hepatocellular carcinoma. Methods: Seventy-three patients with unresectable hepatocellular carcinoma, but without severe liver disease or portal vein occlusion, were randomly assigned to receive either repeated lipiodol chemoembolization (lipiodol, cisplatin (2 mg/kg), lecithin, and gelatin sponge injected into the hepatic artery) plus tamoxifen (40 mg) or tamoxifen alone. The maine end-point was survival. Results: The 37 patients in the lipiodol chemoembolization group received 104 courses (median 3 per patient). By 1 September 1996, 58 patients had died: 30 in the lipiodol chemoembolization group and 28 in the tamoxifen group. There was no difference in survival between the two groups ( p =0.77). The relative risk of death in the lipiodol chemoembolization plus tamoxifen group as compared to the tamoxifen group was 0.92 (95% confidence interval 0.55 to 1.56). At 1 year, survival was 51% and 55%, respectively. An objective tumoral response was more frequently observed in the lipiodol chemoembolization group than in the tamoxifen group (24 versus 5.5%, respectively, p =0.046). Lipiodol chemoembolization caused two deaths and induced signs of liver failure in 51% of the patients assigned to this treatment. Conclusion: In our randomized study, lipiodol chemoembolization did not improve the survival of patients with unresectable hepatocellular carcinoma treated with tamoxifen.
- Subjects :
- Adult
Male
medicine.medical_specialty
Randomization
Carcinoma, Hepatocellular
medicine.medical_treatment
Antineoplastic Agents
Gastroenterology
Liver disease
Internal medicine
medicine
Carcinoma
Humans
Embolization
Chemoembolization, Therapeutic
Survival analysis
Aged
Hepatology
business.industry
Liver Neoplasms
Iodized Oil
Middle Aged
medicine.disease
Survival Analysis
Surgery
Tamoxifen
Hepatocellular carcinoma
Lipiodol
Female
Cisplatin
business
medicine.drug
Subjects
Details
- ISSN :
- 01688278
- Volume :
- 29
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Journal of hepatology
- Accession number :
- edsair.doi.dedup.....b4bdcd9840bf7871a5fbb06134ef9ee2